IRIS Accounts Production v25.1.0.734 04891918 Board of Directors 1.10.23 30.9.24 30.9.24 false true false false false true false Fair value model 69018 97888 101432 85491 188101 114361 17651 69018 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh048919182023-09-30048919182024-09-30048919182023-10-012024-09-30048919182022-09-30048919182022-10-012023-09-30048919182023-09-3004891918ns15:EnglandWales2023-10-012024-09-3004891918ns14:PoundSterling2023-10-012024-09-3004891918ns10:Director12023-10-012024-09-3004891918ns10:PrivateLimitedCompanyLtd2023-10-012024-09-3004891918ns10:SmallEntities2023-10-012024-09-3004891918ns10:AuditExempt-NoAccountantsReport2023-10-012024-09-3004891918ns10:SmallCompaniesRegimeForDirectorsReport2023-10-012024-09-3004891918ns10:SmallCompaniesRegimeForAccounts2023-10-012024-09-3004891918ns10:FullAccounts2023-10-012024-09-300489191812023-10-012024-09-3004891918ns10:Director2422023-09-3004891918ns10:Director2422022-09-3004891918ns10:Director2422023-10-012024-09-3004891918ns10:Director2422022-10-012023-09-3004891918ns10:Director2422024-09-3004891918ns10:Director2422023-09-3004891918ns10:Director22023-10-012024-09-3004891918ns10:CompanySecretary12023-10-012024-09-3004891918ns10:RegisteredOffice2023-10-012024-09-3004891918ns5:CurrentFinancialInstruments2024-09-3004891918ns5:CurrentFinancialInstruments2023-09-3004891918ns5:Non-currentFinancialInstruments2024-09-3004891918ns5:Non-currentFinancialInstruments2023-09-3004891918ns5:ShareCapital2024-09-3004891918ns5:ShareCapital2023-09-3004891918ns5:RevaluationReserve2024-09-3004891918ns5:RevaluationReserve2023-09-3004891918ns5:NetGoodwill2023-10-012024-09-3004891918ns5:IntangibleAssetsOtherThanGoodwill2023-10-012024-09-3004891918ns5:PlantMachinery2023-10-012024-09-3004891918ns5:NetGoodwill2023-09-3004891918ns5:NetGoodwill2024-09-3004891918ns5:NetGoodwill2023-09-3004891918ns5:PlantMachinery2023-09-3004891918ns5:PlantMachinery2024-09-3004891918ns5:PlantMachinery2023-09-3004891918ns5:WithinOneYearns5:CurrentFinancialInstruments2024-09-3004891918ns5:WithinOneYearns5:CurrentFinancialInstruments2023-09-3004891918ns5:Non-currentFinancialInstrumentsns5:MoreThanFiveYears2024-09-3004891918ns5:Non-currentFinancialInstrumentsns5:MoreThanFiveYears2023-09-3004891918ns5:Secured2024-09-3004891918ns5:Secured2023-09-30048919181ns10:Director12023-09-30048919181ns10:Director12022-09-30048919181ns10:Director12023-10-012024-09-30048919181ns10:Director12022-10-012023-09-30048919181ns10:Director12024-09-30048919181ns10:Director12023-09-30
REGISTERED NUMBER: 04891918 (England and Wales)








Unaudited Financial Statements

for the Year Ended 30 September 2024

for

Carterharcourt Medical Ltd.

Carterharcourt Medical Ltd. (Registered number: 04891918)






Contents of the Financial Statements
for the Year Ended 30 September 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Carterharcourt Medical Ltd.

Company Information
for the Year Ended 30 September 2024







DIRECTORS: Mr W G V Harcourt
Mrs C B Harcourt





SECRETARY: Mrs C B Harcourt





REGISTERED OFFICE: The Old Rectory
Church Road
Swindon Village
Gloucester
Gloucestershire
GL51 9RD





REGISTERED NUMBER: 04891918 (England and Wales)





ACCOUNTANTS: TC Group
Cliffe Hill House
22-26 Nottingham Road
Stapleford
NG9 8AA

Carterharcourt Medical Ltd. (Registered number: 04891918)

Balance Sheet
30 September 2024

30.9.24 30.9.23
Notes £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 2,813 3,116
Investment property 6 815,000 820,000
817,813 823,116

CURRENT ASSETS
Debtors 7 56,258 51,977
Cash at bank 54,591 42,923
110,849 94,900
CREDITORS
Amounts falling due within one year 8 72,014 123,716
NET CURRENT ASSETS/(LIABILITIES) 38,835 (28,816 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

856,648

794,300

CREDITORS
Amounts falling due after more than one
year

9

(272,721

)

(272,721

)

PROVISIONS FOR LIABILITIES (42,008 ) (43,334 )
NET ASSETS 541,919 478,245

CAPITAL AND RESERVES
Called up share capital 11 100 100
Revaluation reserve 12 123,914 -
Retained earnings 417,905 478,145
SHAREHOLDERS' FUNDS 541,919 478,245

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 September 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 September 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Carterharcourt Medical Ltd. (Registered number: 04891918)

Balance Sheet - continued
30 September 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 30 April 2025 and were signed on its behalf by:





Mr W G V Harcourt - Director


Carterharcourt Medical Ltd. (Registered number: 04891918)

Notes to the Financial Statements
for the Year Ended 30 September 2024

1. STATUTORY INFORMATION

Carterharcourt Medical Ltd. is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2013, is being amortised evenly over its estimated useful life of five years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 33% on reducing balance and 25% on reducing balance

Tangible assets are initially recorded at cost and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation, less any subsequent depreciation and subsequent accumulated impairment losses.

Investment property
Investment property is included at the open market value of each property as estimated by the Directors as at the Balance Sheet date. The surplus or deficit arising from revaluation is recognised in the Statement of Income and Retained Earnings.

No depreciation is provided on Investment property.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Carterharcourt Medical Ltd. (Registered number: 04891918)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2023 - 4 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 October 2023
and 30 September 2024 10,000
AMORTISATION
At 1 October 2023
and 30 September 2024 10,000
NET BOOK VALUE
At 30 September 2024 -
At 30 September 2023 -

Carterharcourt Medical Ltd. (Registered number: 04891918)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 October 2023 20,955
Additions 858
At 30 September 2024 21,813
DEPRECIATION
At 1 October 2023 17,839
Charge for year 1,161
At 30 September 2024 19,000
NET BOOK VALUE
At 30 September 2024 2,813
At 30 September 2023 3,116

6. INVESTMENT PROPERTY
Total
£   
FAIR VALUE
At 1 October 2023 820,000
Revaluations (5,000 )
At 30 September 2024 815,000
NET BOOK VALUE
At 30 September 2024 815,000
At 30 September 2023 820,000

Fair value at 30 September 2024 is represented by:
£   
Valuation in 2021 750,000
Valuation in 2022 45,000
Valuation in 2023 25,000
Valuation in 2024 (5,000 )
815,000

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.9.24 30.9.23
£    £   
Trade debtors 33,236 42,369
Other debtors 23,022 9,608
56,258 51,977

Carterharcourt Medical Ltd. (Registered number: 04891918)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.9.24 30.9.23
£    £   
Taxation and social security 55,378 43,482
Other creditors 16,636 80,234
72,014 123,716

9. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
30.9.24 30.9.23
£    £   
Other creditors 272,721 272,721

Amounts falling due in more than five years:

Repayable otherwise than by instalments
Property mortgage 272,721 272,721

10. SECURED DEBTS

The following secured debts are included within creditors:

30.9.24 30.9.23
£    £   
Other loans 272,721 272,721

11. CALLED UP SHARE CAPITAL

30.9.24 30.9.23

Ordinary A 48 49
Ordinary B 48 48
Ordinary C 1 1
Ordinary D 1 1
Ordinary E 1 1
Ordinary F 1

12. RESERVES
Revaluation
reserve
£   
P&L - Revaluation movement 123,914

At 30 September 2024 123,914

Carterharcourt Medical Ltd. (Registered number: 04891918)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

13. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 30 September 2024 and 30 September 2023:

30.9.24 30.9.23
£    £   
Mr W G V Harcourt and Mrs C B Harcourt
Balance outstanding at start of year 69,018 97,888
Amounts advanced 101,432 85,491
Amounts repaid (188,101 ) (114,361 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year (17,651 ) 69,018